Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00185575 · ClinicalTrials.gov registry record · NA

Duloxetine for the Treatment of Dysthymia

A NA study of Depressive Disorder, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT00185575 is a NA study of Depressive Disorder that has completed, run by Stanford University. The registered enrollment target is 24 participants, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00185575, a NA study of Depressive Disorder, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more than 2 years.

Conditions Studied

Interventions

  • DRUG duloxetine

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2004-09
Est. Completion 2006-04
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT00185575

The ClinicalTrials.gov registry entry for NCT00185575 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 331-participant average among 47 other Depressive Disorder trials with a reported enrollment target (93% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which duloxetine is the first listed.

NCT00185575 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00185575 about?

NCT00185575 is a clinical study titled "Duloxetine for the Treatment of Dysthymia". The purpose of this study is to test the hypothesis that duloxetine (Cymbalta), in doses of 60 or 120 mg/day, is an effective and tolerable treatment for adult outpatients suffering from dysthymia. Dysthymia is chronic, mild depression characterized by feeling sad or low more days than not for more ...

What is the current status of trial NCT00185575?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2004-09. Estimated completion is 2006-04.

What conditions does trial NCT00185575 study?

This clinical trial studies the following conditions: Depressive Disorder.

What interventions are being tested in trial NCT00185575?

The interventions under investigation include: duloxetine (DRUG).

Who is sponsoring clinical trial NCT00185575?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00185575 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.